Department of Pharmacy, Tajen University, Yen-Pou, Ping Tung Shien, Taiwan.
Evid Based Complement Alternat Med. 2011;2011:987876. doi: 10.1093/ecam/nen078. Epub 2010 Oct 19.
Recently, there have been advances in the development of new substances effective in managing diabetic disorders. Opioid receptors couple multiple systems to result in various biological effects, although opioids are best known for analgesia. In the present review, we used our recent data to describe the advance in plasma glucose-lowering action of herbal products, especially the mediation of β-endorphin in glucose homeostasis of insulin-deficient diabetes. In type 1-like streptozotocin-induced diabetic rats, we identified many products purified from herbs that show a dose-dependent plasma glucose-lowering action. Increase in β-endorphin secretion from the adrenal gland may activate peripheral opioid μ-receptors (MOR) to enhance the expression of muscle glucose transporters and/or to reduce hepatic gluconeogenesis at the gene level, thereby leading to improved glucose utilization in peripheral tissues for amelioration of severe hyperglycemia. It has also been observed that stimulation of α(1)-adrenoceptors (α(1)-ARs) in the adrenal gland by some herbal products is responsible for the increase in β-endorphin secretion via a phospholipase C-protein kinase dependent pathway. However, an increase in β-endorphin secretion from the adrenal gland by herbal products can function via another receptor. New insights into the mediation of endogenous β-endorphin activation of peripheral MOR by herbal products for regulation of glucose homeostasis without the presence of insulin have been established. Therefore, an increase in β-endorphin secretion and/or direct stimulation of peripheral MOR via an insulin-independent action might serve as the potential target for development of a therapeutic agent or promising adjuvant in intensive plasma glucose control.
最近,在开发治疗糖尿病的新物质方面取得了进展。阿片受体与多个系统偶联,产生各种生物学效应,尽管阿片类药物以镇痛作用最为人所知。在本综述中,我们使用最近的数据描述了草药产品降低血糖作用的新进展,特别是β-内啡肽在胰岛素缺乏型糖尿病葡萄糖稳态中的介导作用。在类似于 1 型的链脲佐菌素诱导的糖尿病大鼠中,我们鉴定出许多从草药中纯化的产品具有剂量依赖性的降低血浆葡萄糖作用。肾上腺β-内啡肽分泌的增加可能激活外周阿片 μ 受体(MOR),增强肌肉葡萄糖转运蛋白的表达,或在基因水平上减少肝糖异生,从而改善外周组织对严重高血糖的葡萄糖利用。还观察到,一些草药产品对肾上腺α(1)-肾上腺素能受体(α(1)-ARs)的刺激通过依赖于磷脂酶 C-蛋白激酶的途径导致β-内啡肽分泌增加。然而,草药产品从肾上腺中增加β-内啡肽的分泌可以通过另一种受体起作用。新的研究表明,草药产品通过内源性β-内啡肽激活外周 MOR 来调节葡萄糖稳态,而无需胰岛素的参与。因此,β-内啡肽分泌的增加和/或通过胰岛素独立作用直接刺激外周 MOR 可能成为开发治疗剂或有前途的强化血糖控制辅助剂的潜在目标。